Entrada Therapeutics (TRDA) Prepaid Assets (2020 - 2026)
Entrada Therapeutics' quarterly Prepaid Assets came in at $11.2 million in Q1 2026, down 39.76% year-on-year from $18.6 million in Q1 2025, and up 28.75% quarter-over-quarter from $8.7 million in Q4 2025.
Entrada Therapeutics has reported Prepaid Assets for 7 years, with the latest figure at $11.2 million in Q1 2026.
- For the quarter ending Q1 2026, Prepaid Assets fell 39.76% year-over-year to $11.2 million; the trailing twelve-month figure through Mar 2026 stood at $11.2 million (down 39.76% YoY), and the FY2025 full-year result was $8.7 million, down 46.71% from the prior year.
- Prepaid Assets for Q1 2026 stood at $11.2 million, up from $8.7 million in the prior quarter.
- The five-year high for Prepaid Assets was $24.4 million in Q3 2023, with the low at $8.7 million in Q4 2025.
- Average Prepaid Assets over 5 years is $13.8 million, with a median of $12.1 million recorded in 2024.
- Year-over-year, Prepaid Assets soared 1316.19% in 2022 and slumped 46.71% in 2025.
- Tracing TRDA's Prepaid Assets over 5 years: stood at $21.2 million in 2022, then tumbled by 43.66% to $11.9 million in 2023, then surged by 37.21% to $16.4 million in 2024, then tumbled by 46.71% to $8.7 million in 2025, then gained by 28.75% to $11.2 million in 2026.
- The last three Prepaid Assets figures came in at $11.2 million (Q1 2026), $8.7 million (Q4 2025), and $10.2 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Entrada Therapeutics | 295.78 Mn | 295.78 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 11.23 Mn |
| Dec 31, 2025 | 8.72 Mn |
| Sep 30, 2025 | 10.22 Mn |
| Jun 30, 2025 | 13.95 Mn |
| Mar 31, 2025 | 18.63 Mn |
| Dec 31, 2024 | 16.36 Mn |
| Sep 30, 2024 | 13.39 Mn |
| Jun 30, 2024 | 12.12 Mn |
| Mar 31, 2024 | 9.24 Mn |
| Dec 31, 2023 | 11.92 Mn |
| Sep 30, 2023 | 24.44 Mn |
| Jun 30, 2023 | 9.66 Mn |
| Mar 31, 2023 | 16.21 Mn |
| Dec 31, 2022 | 21.16 Mn |
| Sep 30, 2022 | 19.16 Mn |
| Jun 30, 2022 | 9.65 Mn |
| Mar 31, 2022 | 8.81 Mn |
| Dec 31, 2021 | 7.64 Mn |
| Sep 30, 2021 | 1.35 Mn |
| Dec 31, 2020 | 904,000.00 |